Shukra Pharmaceuticals Ltd. intimates BSE of its upcoming Board Meeting scheduled for May 07, 2026.
The Board will consider and approve the audited financial results for Q4 and FY ending March 31, 2026.
The Board will also recommend a Final Dividend for the financial year 2025-26.
The intimation is made pursuant to SEBI LODR Regulations, specifically Regulation 29.